TransCode Therapeutics, Inc. has 14 Schedule 13D or 13G filings on record since 2025-08-14. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| CK Life Sciences Int'l., (Holdings) Inc. | 83.9% | 14,134,481 | SCHEDULE 13D/A, 2026-08-03 | 2026-08-03 |
| Unleash Immuno Oncolytics, Inc. | 9.94% | 300,000 | SCHEDULE 13G, 2026-07-28 | 2026-07-23 |
| YA II PN, Ltd. | 9.9% | 101,772 | SCHEDULE 13G, 2026-04-20 | 2026-04-15 |
| Elena Rosa Braci | 6.17% | 186,236 | SCHEDULE 13G, 2026-07-28 | 2026-07-23 |
| Daniel Eduardo Katzman | 5.16% | 155,611 | SCHEDULE 13G, 2026-07-28 | 2026-07-23 |
| Sabby Management, LLC | 4.9% | 41,601 | SCHEDULE 13G/A, 2026-01-07 | 2025-12-31 |
| Anson Funds Management LP | 0.1% | 27,125 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| The Goldman Sachs Group, Inc. | 0% | 82 | SCHEDULE 13G/A, 2025-11-10 | 2025-09-30 |
Purpose of Transaction (Item 4)
CK Life Sciences Int'l., (Holdings) Inc.
Item 4 of Schedule 13D is hereby amended by adding the below disclosure following the last paragraph of Item 4: On August 3, 2026, upon obtaining the consent of a majority of the holders of the Preferred Stock, and the approval of the Company's Board of Directors, the Company filed a Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock and Series B Non-Voting Convertible Preferred Stock (the "Second Amended and Restated Certificate of Designation") with the Secretary of State of the State of Delaware. The Second Amended and Restated Certificate of Designation amended Section 6.3.3 of the Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock and Series B Non-Voting Convertible Preferred Stock ("Amended and Restated Certificate of Designation") to remove the requirement of 60 days' notice to change and/or waive the beneficial ownership limitation set forth in the Amended and Restated Certificate of Designation. The Second Amended and Restated Certificate of Designation effected no other changes to the Amended and Restated Certificate of Designation other than the foregoing, and no additional securities were issued or sold in connection with the filing. The foregoing description of the Second Amended and Restated Certificate of Designation does not purport to be complete and is qualified in its …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-08-03; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | The Goldman Sachs Group, Inc. | 5.9% | SCHEDULE 13G |
| 2025-08-14 | Anson Funds Management LP | 0.1% | SCHEDULE 13G/A |
| 2025-10-16 | CK Life Sciences Int'l., (Holdings) Inc. | 9.1% | SCHEDULE 13D |
| 2025-10-28 | CK Life Sciences Int'l., (Holdings) Inc. | 9.1% | SCHEDULE 13D/A |
| 2025-11-10 | The Goldman Sachs Group, Inc. | 0% | SCHEDULE 13G/A |
| 2026-01-07 | Sabby Management, LLC | 4.9% | SCHEDULE 13G/A |
| 2026-04-20 | YA II PN, Ltd. | 9.9% | SCHEDULE 13G |
| 2026-07-17 | CK Life Sciences Int'l., (Holdings) Inc. | 8.8% | SCHEDULE 13D/A |
| 2026-07-23 | CK Life Sciences Int'l., (Holdings) Inc. | 9.9% | SCHEDULE 13D/A |
| 2026-07-27 | CK Life Sciences Int'l., (Holdings) Inc. | 83.9% | SCHEDULE 13D/A |
| 2026-07-28 | Daniel Eduardo Katzman | 5.16% | SCHEDULE 13G |
| 2026-07-28 | Elena Rosa Braci | 6.17% | SCHEDULE 13G |
| 2026-07-28 | Unleash Immuno Oncolytics, Inc. | 9.94% | SCHEDULE 13G |
| 2026-08-03 | CK Life Sciences Int'l., (Holdings) Inc. | 83.9% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for TransCode Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.